The alkylating chemotherapeutic temozolomide induces metabolic stress in IDH1-mutant cancers and potentiates NAD+ depletion-mediated cytotoxicity
Unfortunately no NAMPT inhibitors have been approved for clinical use, although one is currently in trial.
No comments:
Post a Comment